Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12400 INCYTE CORPORATION (Exact name of registrant as specified in its charter) Delaware 94-3136539 (State or ...

Incyte Corporation (NASDAQ:INCY) Q4 2021 Earnings Conference Call February 8, 2022 8:00 AM ET Company Participants Christine Chiou – Head-Investor Relations Hervé Hoppenot – Chairman, President and Chief Executive Officer Barry Flannelly – Executive Vice President and General Manager-North America Steven Stein – Executive Vice President and Chief Medical Officer Christiana Stamoulis – Executive Vice President and Chief Financial Officer Conference Call Participants Vikram Purohit – Morgan Stanley Brian Abra ...

Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness ...

| --- | --- | --- | --- | --- | --- | --- | |---------------------------------------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Hervé Hoppenot, CEO | | | | | | | | JP MORGAN HEALTHCARE CONFERENCE JANUARY 10, 2022 | | | | | | | | | | | | | | | Forward-looking statements 2 Except for the historical information set forth herein, the matters set forth in this presentation contain predictions, estimates, and other forward-looking ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------------------------------------|-------|-------|------------------|--------|-------|-------|-------|-------| | | | | 官方 \| W | | | | | | | | | | . 000 00 10 100 | \| ■ ■ | | | | | | Incyte | | | | | | | | | | 2021 Third Quarter Financial and Corporate Update NOVEMBER 2, 2021 | | | | | | | | | | | | | | | | | | | FORWARD-LOOKING STATEMENTS 2 Except for the historical information set forth herein, the matters set for ...

Incyte Corporation (NASDAQ:INCY) Q3 2021 Earnings Conference Call November 2, 2021 8:00 AM ET Company Participants Christine Chiou – Head of Investor Relations Herve Hoppenot – Chairman and Chief Executive Officer Barry Flannelly – Executive Vice President Steven Stein – Chief Medical Officer Christiana Stamoulis – Chief Financial Officer Conference Call Participants Tazeen Ahmad – Bank of America Brian Abrahams – RBC Cory Kasimov – JP Morgan Kripa Devarakonda – Truist Securities Salveen Rachael – Goldman S ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12400 INCYTE CORPORATION (Exact name of registrant as specified in its charter) Delaware 94-3136539 (Stat ...

| --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------------------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | SOLVE Incyte) ON. GVHD UPDATE SEPTEMBER 27, 2021 | | | | | | | | | | | | | | | | | FORWARD LOOKING STATEMENTS 2 Except for the historical information set forth herein, the matters set forth in this presentation, including statements regarding the potential for growth and diversification of Incyte's revenues; the " ...

| --- | --- | --- | --- | --- | --- | --- | --- | |---------------------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | OPZELURA TM | | | | | | | | | (ruxolitinib) cream | | | | | | | | | FDA Approval Call | | | | | | | | | SEPTEMBER 22, 2021 | | | | | | | | | | | | | | | | | FORWARD LOOKING STATEMENTS 2 Except for the historical information set forth he ...

Incyte Corporation (NASDAQ:INCY) Q2 2021 Earnings Conference Call August 3, 2021 8:00 AM ET Company Participants Christine Chiou - Senior Director, Investor Relations Hervé Hoppenot - Chairman, President and Chief Executive Officer Barry Flannelly - Executive Vice President and General Manager, North America Steven Stein - Executive Vice President and Chief Medical Officer Christiana Stamoulis - Executive Vice President and Chief Financial Officer Conference Call Participants Salveen Richter - Goldman Sachs ...